• Explore /
  • Poster
  • / Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).

Abstract Video & Slides Poster

Authors

Delvys Rodriguez-Abreu, Sr

Delvys Rodriguez-Abreu

Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, Spain

Delvys Rodriguez-Abreu , Steven Francis Powell , Maximilian Hochmair , Shirish M. Gadgeel , Emilio Esteban , Enriqueta Felip , Giovanna Speranza , Manuel Dómine Gomez , Susanna Y. Cheng , Helge Bischoff , Nir Peled , Martin Reck , Rina Hui , Edward B. Garon , Michael J. Boyer , Takayasu Kurata , Jing Yang , Tuba Bas , Fabricio G. Souza , Marina Chiara Garassino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02578680

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9582)

DOI

10.1200/JCO.2020.38.15_suppl.9582

Abstract #

9582

Poster Bd #

348

Abstract Disclosures

Similar Posters

First Author: Shirish M. Gadgeel

First Author: Martin Reck

First Author: Marina Chiara Garassino

Poster

2024 ASCO Breakthrough

Intracranial outcomes of 1L selpercatinib in advanced <em>RET</em> fusion-positive NSCLC: LIBRETTO-431 study.

Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.

First Author: Minji Uh